Member of the International College of Neuropsychopharmacology
Member of the Asian Pacific Society for Neurochemistry/International Society for Neurochemistry
「永信李天德醫藥基金會得獎人聯誼會」會員
論文及期刊發表
Early Prediction of Clinical Response in Schizophrenia Patients Receiving Atypical Antipsychotic Zotepine.
Factors affecting time to rehospitalization for patients with major depressive disorder.
Factors affecting time to rehospitalization for Chinese schizophrenic patients in Taiwan.
Factors predicting transferal after psychiatric emergency management in the elderly.
Mirtazapine-associated Hair Loss.
Time to rehospitalization in patients with major depression vs. those with schizophrenia or bipolar I disorder in a public psychiatric hospital.
Glutamate signaling in the pathophysiology and therapy of schizophrenia.
Clozapine Protects Bone Mineral Density in Female Patients with Schizophrenia.
Optimizing the early prediction model for symptomatic remission with acute treatment for schizophrenia.
NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer’s Disease.
Potential Blood Biomarker for Disease Severity in the Taiwanese Population with Alzheimer’s disease.
Clinical symptoms, mainly negative symptoms, mediate the influence of neurocognition and social cognition on functional outcome of schizophrenia.
Synergistic Effects of COMT and TPH2 on Social Cognition.
Benzoate, a D-Amino Acid Oxidase Inhibitor, for the Treatment of Early-Phase Alzheimer’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial.
Distinctively higher plasma G72 protein levels in patients with schizophrenia than in healthy individuals.
NMDA neurotransmission dysfunction in mild cognitive impairment and Alzheimer’s disease.
Sex-specific factors for bone density in patients with schizophrenia.
Donepezil improved cognitive deficits in a patient with neurosyphilis.
Decreased mRNA expression for the two subunits of system xc- , SLC3A2 and SLC7A11, in WBC in patients with schizophrenia: evidence in support of the hypo-glutamatergic hypothesis of schizophrenia.
Mania following ketamine abuse.
Spontaneous remission of ketamine-withdrawal related depression.
Hypothyroidism may exacerbate valproate-related hyperammonemic delirium.
Effects of antipsychotics on bone mineral density in patients with schizophrenia: Gender differences.
Venous thromboembolism following dantrolene treatment for neuroleptic malignant syndrome.
β-hydroxybutyrate, pyruvate and metabolic profiles in patients with schizophrenia: A case control study.
Brexpiprazole for the treatment of schizophrenia.
New treatment strategies of depression: Based on mechanisms related to neuroplasticity.
PICK1 genetic variation and cognitive function in patients with schizophrenia.
Gender differences in susceptibility to schizophrenia: potential implication of neurosteroids.
Bupropion interferes with the image diagnosis of Parkinson disease.
Blood levels of D-amino acid oxidase vs. D-amino acids in reflecting cognitive aging.
Genetic biomarkers on cognitive aging.
Increased serum levels of cysteine in patients with schizophrenia: A potential marker of cognitive function preservation.
Medications used for cognitive enhancement in patients with schizophrenia, bipolar Disorder, Alzheimer’s disease, and Parkinson’s disease.
Brain stimulation in Alzheimer’s disease.
Sodium benzoate, a D-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: a randomized, double-Blind, placebo-controlled trial.
Combination of G72 genetic variation and G72 protein level to detect schizophrenia: Machine learning approaches. (#Equal contribution)
Altered mRNA expressions for N-methyl-D-aspartate receptor-related genes in WBC of patients with major depressive disorder.
Early identification and intervention of schizophrenia: insight from hypotheses of glutamate dysfunction and oxidative stress.
Long-term Use of Clozapine is Protective for Bone Density in Patients with Schizophrenia.
Effects of donepezil on cognition and global functioning in patients with delayed encephalopathy after carbon monoxide poisoning – A case series.
Effect of N-methyl-D-aspartate-receptor-enhancing agents on cognition in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials.
The Role of N-methyl-D-aspartate Receptor Neurotransmission and Precision Medicine in Behavioral and Psychological Symptoms of Dementia.
Sodium Benzoate for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD): a Randomized, Double-blind, Placebo-controlled, 6-week Trial.
pLG72 levels increase in early phase of Alzheimer's disease but decrease in late phase
D-glutamate, D-serine, and D-alanine differ in their roles in cognitive decline in patients with Alzheimer’s disease or mild cognitive impairment.
C-Reactive Protein is Associated With Severity of Thought and Language Dysfunction in Patients With Schizophrenia.
Paliperidone is associated with reduced risk of severe hepatic outcome in patients with schizophrenia and viral hepatitis: A nationwide population-based cohort study.
Novel Treatment for the hardest-to-treat Schizophrenia: Dual Activation of NMDA Receptor and Antioxidant.
Editorial: Glutamate-related biomarkers for neuropsychiatric disorders.
Polymorphism in the LASP1 gene promoter region alters cognitive functions of patients with schizophrenia. (#Equal contribution)
The Role of N-methyl-D-aspartate Receptor on Late-Life Depression.
Survey of NMDA receptor-related biomarkers for depression.
Precision Psychiatry Applications with Pharmacogenomics: Artificial Intelligence and Machine Learning Approaches.
Precision Medicine of Sodium Benzoate for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD).
Genetic Effects of DISC1 and G72 (DAOA) on Visual Learning of Patients with Schizophrenia. (#Equal contribution)
Efficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: a systematic review and meta-analysis of double-blind randomised controlled trials. (#Equal contribution)
D-Glutamate and gut microbiota in Alzheimer’s disease.
An ensemble approach to predict schizophrenia using protein data in the N-methyl-D-aspartate receptor (NMDAR) and tryptophan catabolic pathways.
Relevant Applications of Generative Adversarial Networks in Drug Design and Discovery: Molecular De Novo Design, Dimensionality Reduction, and De Novo Peptide and Protein Design.
D2 dopamine receptor gene (DRD2) Taq1A (rs1800497) affects bone density.
Trough melatonin levels differ between early and late phases of Alzheimer disease.
Involvement of Cholinergic, Adrenergic, and Glutamatergic Network Modulation with Cognitive Dysfunction in Alzheimer’s Disease.
Plasma D-glutamate levels for detecting mild cognitive impairment and Alzheimer’s disease: Machine learning approaches. (#Equal contribution)
Machine learning and novel biomarkers for the diagnosis of Alzheimer’s disease.
Applying a bagging ensemble machine learning approach to predict functional outcome of schizophrenia with clinical symptoms and cognitive functions.
Effect of Sodium Benzoate on Cognitive Function Among Patients With Behavioral and Psychological Symptoms of Dementia: Secondary Analysis of a Randomized Clinical Trial.
Prediction of Functional Outcomes of Schizophrenia with Genetic Biomarkers Using a Bagging Ensemble Machine Learning Method with Feature Selection.
Reply: Trough melatonin levels have no physiological or clinical relevance.
Brain activity of benzoate, a D-amino acid oxidase inhibitor, in patients with mild cognitive impairment in a randomized, double-blind, placebo controlled clinical trial.
Molecular Basis of Late-Life Depression.
Novel Biomarkers of Alzheimer’s Disease: Based upon NMDAR Hypoactivation and Oxidative Stress.
Characterization of Potential Protein Biomarkers for Major Depressive Disorder Using Matrix-Assisted Laser Desorption Ionization/Time-of-Flight Mass Spectrometry (#Equal contribution).
Deep Learning with Neuroimaging and Genomics in Alzheimer's Disease.
Novel therapeutic approaches for Alzheimer’s disease: an updated review.
The relationships between hyperprolactinemia, metabolic disturbance, and sexual dysfunction in patients with schizophrenia under olanzapine treatment (#Equal contribution).
From menopause to neurodegeneration - molecular basis and potential therapy.
Cystine/Glutamate Antiporter in Schizophrenia: From Molecular Mechanism to Novel Biomarker and Treatment.
D-Amino Acids and pLG72 in Alzheimer’s Disease and Schizophrenia.
Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments.
Plasma glutathione levels decreased with cognitive decline among people with mild cognitive impairment (MCI): a two-year prospective study.
Logistic ridge regression to predict bipolar disorder using mRNA expression levels in the N-methyl-D-aspartate receptor genes.
Distinctively lower DISC1 mRNA levels in patients with schizophrenia, especially in those with higher positive, negative, and depressive symptoms.
Effects of sodium benzoate, a D-amino acid oxidase inhibitor, on perceived stress and cognitive function among patients with late-life depression: A randomized, double-blind, sertraline- and placebo-controlled trial.
A bagging ensemble machine learning framework to predict overall cognitive function of schizophrenia patients with cognitive domains and tests.
De Novo Peptide and Protein Design Using Generative Adversarial Networks: An Update.
Suicide ideation among outpatients with alcohol use disorder.
Blood D-amino acid oxidase (DAO) levels increased with cognitive decline among people with mild cognitive impairment (MCI): a two-year prospective study.
Diagnosing Alzheimer’s disease specifically and sensitively with pLG72 and cystine/glutamate antiporter SLC7A11 as blood biomarkers.
Targeting D-Amino Acid Oxidase (DAAO) for the Treatment of Schizophrenia: Rationale and Current Status of Research.
Endogenous Antioxidants Predicted Outcome and Increased after Treatment: a Benzoate Dose-finding, Randomized, Double-blind, Placebo-controlled Trial for Alzheimer's Disease.
Ketamine, benzoate, and sarcosine for treating depression.
